Houston health tech startup launches COVID-19 vaccine management tool

inoculation innovation

Image via luminaremed.com

Houston-based health care software startup Luminare Inc. is arming soldiers in the coronavirus vaccination campaign with technology to help smooth the inoculation process.

Luminare, which launched with the mission of combating sepsis, switched gears after the onset of the coronavirus pandemic to help combat the virus' spread. One of the ways it's doing that is with Innoculate (a mash-up of "innovate" and "inoculate"). The new platform enables organizations like public health departments, fire departments, school systems, and businesses to manage high-volume vaccination initiatives.

Among other benefits, Innoculate automates vaccination sign-ups and scheduling, tracks the number of vaccine batches available, flags previous allergic reactions among vaccine recipients, and helps achieve compliance with federal, state and local health care requirements.

"Usually when you hear news of a new batch of vaccines headed your way, there is dread at the management and distribution overhead. Not anymore," Dr. Sarma Velamuri, CEO of Luminare, says in a release. "Innoculate will help streamline the vaccination process in the fight against COVID-19 and allow for hundreds of thousands of people to get vaccines easily."

One of the first customers of Innoculate is the Corpus Christi-Nueces County Public Health District. Innoculate helped the district vaccinate 9,000 people during the first week of its vaccination effort. Peter Collins, chief information officer of the City of Corpus Christi, says Innoculate allows more vaccinations to be done without adding administrative burdens.

Corpus Christi-Nueces County Public Health District was the first government outfit to use Innoculate. The district also uses Luminare's Quickscreen COVID-19 screening and testing tool.

Dallas County Health and Human Services also is adopting Innoculate. On January 27, Dallas County approved a 12-month contract with Luminare worth up to $601,500.

Other new customers that are lined up for Innoculate include the Abilene-Taylor County Public Health District, Wichita Falls-Wichita County Public Health District, and Brenham-based Blinn College District. Innoculate deals are being finalized with 13 other city and county governments.

Luminare says it wants to "help as many cities and counties in the U.S. that we can." The company asks organizations seeking help with coronavirus vaccination campaigns to email mike.gilbert@luminaremed.com or info@luminaremed.com.

Luminare was founded in 2014 with the goal of preventing sepsis, a life-threatening reaction to a host of infections that triggers about one-third of U.S. hospital deaths. Its sepsis-targeted software is called Sagitta.

After the coronavirus began spreading, Luminare tweaked its sepsis-detection platform, called Quickscreen, to produce a free online self-assessment for people who suspect they've been infected with the virus. The startup was honored for this work as COVID Phoenix in Houston Exponential's inaugural awards program, The Listies. Now, it has added Innoculate to its pandemic-fighting arsenal.

Luminare, based at Texas Medical Center's innovation campus, is a 2018 graduate of the TMCx accelerator. According to Crunchbase, the company has collected more than $1.6 million in funding.

From Your Site Articles
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Texas tops ranking of best state for investors in new report

by the numbers

Texas ranks third on a new list of the best states for investors and startups.

Investment platform BrokerChooser weighed five factors to come up with its ranking:

  • 2024 Google search volume for terms related to investing
  • Number of investors
  • Number of businesses receiving investments in 2024
  • Total amount of capital invested in businesses in 2024
  • Percentage change in amount of investment from 2019 to 2024

Based on those figures, provided mostly by Crunchbase, Texas sits at No. 3 on the list, behind No. 1 California and No. 2 New York.

Especially noteworthy for Texas is its investment total for 2024: more than $164.5 billion. From 2019 to 2024, the state saw a 440 percent jump in business investments, according to BrokerChooser. The same percentages are 204 percent for California and 396 percent for New York.

“There is definitely development and diversification in the American investment landscape, with impressive growth in areas that used to fly under the radar,” says Adam Nasli, head analyst at BrokerChooser.

According to Crunchbase, funding for Texas startups is off to a strong start in 2025. In the first three months of this year, venture capital investors poured nearly $2.9 billion into Lone Star State companies, Crunchbase data shows. Crunchbase attributes that healthy dollar amount to “enthusiasm around cybersecurity, defense tech, robotics, and de-extincting mammoths.”

During the first quarter of this year, roughly two-thirds of VC funding in Texas went to just five companies, says Crunchbase. Those companies are Austin-based Apptronik, Austin-based Colossal Biosciences, Dallas-based Island, Austin-based NinjaOne, and Austin-based Saronic.

Autonomous truck company rolls out driverless Houston-Dallas route

up and running

Houston is helping drive the evolution of self-driving freight trucks.

In October, Aurora opened a more than 90,000-square-foot terminal at a Fallbrook Drive logistics hub in northwest Houston to support the launch of its first “lane” for driverless trucks—a Houston-to-Dallas route on the Interstate 45 corridor. Aurora opened its Dallas-area terminal in April and the company began regular driverless customer deliveries between the two Texas cities on April 27.

Close to half of all truck freight in Texas moves along I-45 between Houston and Dallas.

“Now, we are the first company to successfully and safely operate a commercial driverless trucking service on public roads. Riding in the back seat for our inaugural trip was an honor of a lifetime – the Aurora Driver performed perfectly and it’s a moment I’ll never forget,” Chris Urmson, CEO and co-founder of Pittsburgh-based Aurora, said in a news release.

Aurora produces software that controls autonomous vehicles and is known for its flagship product, the Aurora Driver. The software is installed in Volvo and Paccar trucks, the latter of which includes brands like Kenworth and Peterbilt.

Aurora previously hauled more than 75 loads per week under the supervision of vehicle operators from Houston to Dallas and Fort Worth to El Paso for customers in its pilot project, including FedEx, Uber Freight and Werner. To date, it has completed over 1,200 miles without a driver.

The company launched its new Houston to Dallas route with customers Uber Freight and Hirschbach Motor Lines, which ran supervised commercial pilots with Aurora.

“Transforming an old school industry like trucking is never easy, but we can’t ignore the safety and efficiency benefits this technology can deliver. Autonomous trucks aren’t just going to help grow our business – they’re also going to give our drivers better lives by handling the lengthier and less desirable routes,” Richard Stocking, CEO of Hirschbach Motor Lines, added in the statement.

The company plans to expand its service to El Paso and Phoenix by the end of 2025.

“These new, autonomous semis on the I-45 corridor will efficiently move products, create jobs, and help make our roadways safer,” Gov. Greg Abbott added in the release. “Texas offers businesses the freedom to succeed, and the Aurora Driver will further spur economic growth and job creation in Texas. Together through innovation, we will build a stronger, more prosperous Texas for generations.”

In July, Aurora said it raised $820 million in capital to fuel its growth—growth that’s being accompanied by scrutiny.

In light of recent controversies surrounding self-driving vehicles, the International Brotherhood of Teamsters, whose union members include over-the-road truckers, recently sent a letter to Lt. Gov. Dan Patrick calling for a ban on autonomous vehicles in Texas.

“The Teamsters believe that a human operator is needed in every vehicle—and that goes beyond partisan politics,” the letter states. “State legislators have a solemn duty in this matter to keep dangerous autonomous vehicles off our streets and keep Texans safe. Autonomous vehicles are not ready for prime time, and we urge you to act before someone in our community gets killed.”

Houston cell therapy company launches second-phase clinical trial

fighting cancer

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.

View All Listings
X

INNOVATIONMAP EMAILS ARE AWESOME